Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

673

Employees673

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

673

Employees673

CYTK Key Statistics

Market cap

7.50B

Market cap7.50B

Price-Earnings ratio

-9.31

Price-Earnings ratio-9.31

Dividend yield

—

Dividend yield—

Average volume

2.06M

Average volume2.06M

High today

$61.92

High today$61.92

Low today

$59.00

Low today$59.00

Open price

$61.03

Open price$61.03

Volume

2.09M

Volume2.09M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$29.31

52 Week low$29.31

Stock Snapshot

As of today, Cytokinetics(CYTK) shares are valued at $59.00. The company's market cap stands at 7.5B, with a P/E ratio of -9.31.

On 2026-03-17, Cytokinetics(CYTK) stock moved within a range of $59.00 to $61.92. With shares now at $59.00, the stock is trading 0.0% above its intraday low and -4.7% below the session's peak.

Trading volume for Cytokinetics(CYTK) stock has reached 2.09M, versus its average volume of 2.06M.

The stock's 52-week range extends from a low of $29.31 to a high of $70.98.

CYTK News

TipRanks 8h

Cytokinetics Executive Makes Notable Insider Stock Move

New insider activity at Cytokinetics ( (CYTK) ) has taken place on March 16, 2026. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful inve...

Simply Wall St 9h

Cytokinetics MYQORZO Data Sheds Light On oHCM Outlook And Valuation

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. T...

Analyst ratings

86%

of 21 ratings

Buy

85.7%

Hold

14.3%

Sell

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.